|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ratios of the main proteins found in PD patient brain inclusions that can be measured in the CSF appear to have value as short- to mid-term predictors of dementia.
|
30423201 |
2018 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Three studies on stroke reported mixed findings but were limited due to the small number of patients undergoing CSF examination, whilst neurosyphilis continued to be reported as a common cause of dementia in studies from North Africa.
|
28859081 |
2017 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included 768 patients (subjective cognitive decline (SCD, n = 194), mild cognitive impairment (MCI, n = 127), dementia (AD and non-AD, n = 447) with amyloid-β PET and CSF Aβ<sub>42</sub> measurement within 1 year.
|
31810489 |
2019 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subjects with dementia and Mild Cognitive Impairment (MCI) due to AD have been found to have higher CSF cortisol levels than cognitively healthy controls.
|
30881301 |
2019 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 1,081 adults without dementia (375 healthy subjects and 706 individuals with mild cognitive impairment) were recruited from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to test the influence of BDNF Val66Met polymorphism on cognitive impairment, brain structure atrophy, and change in the levels of CSF biomarkers.
|
30775992 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The finding that amnestic MCI based on brief neuropsychological assessment is significantly associated with CSF biomarkers for cognitive decline and Alzheimer's disease is in accordance with longitudinal studies that find memory impairment; both in itself and especially in combination with other cognitive deficit to constitute a risk factor for subsequent cognitive decline and dementia.
|
30614807 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Performance of the CSF biomarkers was optimal in the asymptomatic versus Alzheimer's disease dementia comparison (AUC ≥0·90 for all except Aβ<sub>1-40</sub> [0·59, 0·45-0·72]).
|
30172624 |
2018 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is elevated in cerebrospinal fluid in HIV- associated dementia; in addition, therapeutic GM-CSF elevates plasma viral load.
|
11834953 |
2002 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To examine the disparity in practitioner attitudes and clinical practice relating to the use of CSF biomarkers for dementia diagnosis across Europe.
|
28826189 |
2017 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF tau and <sup>18</sup>F-AV-1451 have equal performance in early clinical stages of AD, but <sup>18</sup>F-AV-1451 is superior in the dementia stage, and exhibits close to perfect diagnostic performance for mild to moderate AD.
|
29321235 |
2018 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this multicentre study in clinical settings, we assessed the accuracy of optimized procedures for FDG-PET brain metabolism and CSF classifications in predicting or excluding the conversion to Alzheimer's disease (AD) dementia and non-AD dementias.
|
29387532 |
2018 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers.
|
28317649 |
2017 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A diagnosis of dementia is currently made in terms of probability and is based on clinical evaluation (neuropsycological tests) as well as on the results of morphological imaging investigations (MRI) that can be supported by biohumoral (CSF analysis), and functional imaging only in the case of uncertain diagnosis of disease.
|
31802055 |
2020 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
By a survey, we aimed to do a "selfie" of the use and diffusion of CSF biomarkers of dementia in Italy, the standardization of pre-analytical procedures, the harmonization of ranges, and the participation to Quality Control programs.
|
27911328 |
2017 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.
|
31836810 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the prognostic utility of identifying longitudinal neuropsychological decline along with single cognitive exam and Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers in predicting dementia.
|
31104015 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, looking into the multifactorial nature of AD and the overlapping pathology with other forms of dementia, it is important to integrate the core CSF biomarkers with a broader panel of other biomarkers reflecting different aspects of pathology.
|
30770953 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic models were developed by Cox regression with patient characteristics, MRI, and/or CSF biomarkers to predict clinical progression to MCI or dementia.
|
30987684 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Applying CSF biomarker ratios, rather than their single values could represent a useful tool, especially for the differential diagnosis of different forms of dementia.
|
28726050 |
2017 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The evaluation of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) (β-amyloid, t-tau, p-tau) can be used to estimate the risk of developing dementia in patients at the pre-clinical stages of AD, i.e. subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
|
30509028 |
2018 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
AD diagnosis (MCI or dementia) with normal CSF biomarkers is a rare condition.
|
29318973 |
2018 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers.
|
29017593 |
2017 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potential predictors included CSF biomarkers, cognitive performance (verbal learning and memory), apolipoprotein E (APOE) ε4 genotype, medial temporal lobe atrophy, family history of dementia, depressive symptoms, and vascular factors, including the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) risk score.
|
31805990 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thereafter, we focused on the four miRNAs that showed group differences and measured their content in neurally derived blood EVs isolated from 63 subjects: 16 patients with early stage dementia and a CSF Aβ42+ tau profile consistent with AD, 16 individuals with mild cognitive impairment (MCI) and an AD CSF profile, and 31 cognitively intact controls with normal CSF Aβ42+ tau levels.
|
31849573 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further suggest that among those patients with substantial cervical stenosis (extensive enough to block CSF circulation in the cervical area as identified by cine MRI) appropriate comparative clinical studies could be undertaken to demarcate associations with presenile dementia, sleep disturbance and posterior fossa dysfunction.
|
30037601 |
2018 |